Welcome to our dedicated page for Procept Biorobotics news (Ticker: PRCT), a resource for investors and traders seeking the latest updates and insights on Procept Biorobotics stock.
PROCEPT BioRobotics Corporation (Nasdaq: PRCT) is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. News about PROCEPT BioRobotics frequently centers on its AQUABEAM and HYDROS Robotic Systems, which deliver Aquablation therapy for benign prostatic hyperplasia (BPH) and are being evaluated in clinical studies for localized prostate cancer.
Investors and clinicians following PRCT news can expect regular updates on quarterly financial results, revenue guidance, and operating metrics such as U.S. system placements, handpiece and consumable revenue, and international performance. The company issues detailed earnings press releases and hosts conference calls and webcasts to discuss its results and outlook.
Company news also covers clinical and regulatory milestones. Examples include progress in the WATER IV Prostate Cancer Trial, which compares Aquablation therapy with radical prostatectomy, and developments related to reimbursement, such as the assignment of a Category I CPT code for Aquablation therapy in the Medicare Proposed Physician Fee Schedule. These items provide insight into how the therapy is being integrated into clinical practice and payment systems.
Additional PRCT headlines highlight participation in healthcare and investor conferences, executive leadership updates, and commentary on the growing body of peer-reviewed publications supporting Aquablation therapy. For anyone tracking the evolution of robotic urology treatments, the PROCEPT BioRobotics news feed offers a centralized view of financial performance, clinical research, reimbursement changes, and corporate events related to Aquablation therapy and the company’s robotic platforms.
PROCEPT BioRobotics reported strong Q3 2024 results with total revenue of $58.4 million, up 66% year-over-year. U.S. revenue grew 62% to $52.2 million, while international revenue increased 122% to $6.2 million. The company sold 45 robotic systems in the U.S. at an average price of $432,000. Gross margin reached a record 63.2%, up from 53.8% in the prior year. The company increased its 2024 guidance, projecting revenue of $222.5-223.0 million and improved its adjusted EBITDA loss forecast to $60.0 million. Cash position remained strong at $199.8 million as of September 30, 2024.
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its plans to release third quarter 2024 financial results on October 28, 2024, before the market opens. The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss the results.
Interested parties can access the call through a webcast link or a dial-in registration for sell-side research analysts. The live audio webcast and an archived recording will be available on the company's investor relations website. The webcast replay will be accessible for at least 90 days after the event.
PROCEPT BioRobotics (Nasdaq: PRCT) has received FDA approval to initiate a pivotal randomized clinical study for prostate cancer treatment. The WATER IV PCa trial will compare Aquablation therapy to radical prostatectomy in men with Grade Group 1 to 3 localized prostate cancer. This global multicenter study will enroll up to 280 patients across 50 centers, with a 10-year follow-up period.
The FDA has also granted Breakthrough Device Designation for Aquablation therapy in prostate cancer treatment. The study's co-primary endpoint focuses on morbidity at six months, with longer-term follow-up assessing treatment-related harm reduction and oncologic events. This trial could potentially revolutionize localized prostate cancer treatment for millions of men.
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston. The company's management team is scheduled to present on Wednesday, September 4, 2024, at 1:30 p.m. Eastern Time.
Investors and interested parties can access a live webcast of the presentation through the company's website at https://ir.procept-biorobotics.com. The webcast will also be archived for at least 90 days after the event, allowing for later viewing. This presentation offers an opportunity for PROCEPT BioRobotics to showcase its innovative urological solutions and connect with healthcare industry professionals and investors.
PROCEPT BioRobotics (Nasdaq: PRCT) has announced FDA 510(k) clearance for its HYDROS™ Robotic System, a next-generation platform for Aquablation® therapy. This AI-powered system is designed to improve efficiency, enhance surgeon experience, and deliver more accurate treatment plans for better clinical outcomes in urology.
Key features of HYDROS include:
- FirstAssist AI™ for treatment planning
- Advanced image guidance with integrated ultrasound and cystoscopy
- Robotic resection using a heat-free waterjet
- Streamlined workflow with a single-footprint integrated tower
The company expects HYDROS to be fully available in the current quarter across U.S. hospitals. PROCEPT BioRobotics has reaffirmed its 2024 financial guidance following this announcement.
Jupiter Endovascular, a medical technology startup, has exited stealth mode with $21 million in new financing to fund a pivotal trial for Pulmonary Embolism. The company is developing a new class of endovascular procedures using Endoportal Control™ technology, which aims to bring the precision of direct surgical access to catheter-based interventions. Carl J. St. Bernard has been appointed as CEO, bringing over 30 years of experience in the life sciences industry.
The funding round, led by Sonder Capital with participation from strategic investors, will support the upcoming pivotal trial and development of additional clinical applications. Jupiter's technology addresses limitations in catheter-based therapies by providing stability and control within complex cardiovascular anatomies, potentially revolutionizing treatment for millions of patients worldwide.
Neptune Medical, a medical device innovator, has announced a successful $97 million Series D financing and the spinout of its subsidiary, Jupiter Endovascular. The financing round saw significant participation from Sonder Capital and Olympus of the Americas, along with other existing and new investors. This strategic move allows Neptune Medical to focus on gastrointestinal robotics, while Jupiter Endovascular will concentrate on its novel endovascular technology platform.
The financing will strengthen Neptune Medical's position in the GI space, as evidenced by the recent appointment of Dr. Fred Moll, a medical robotics pioneer, as Chairman of the Board. Both companies aim to lead innovation in their respective specialties, with Neptune pushing boundaries in GI robotics and Jupiter revolutionizing endovascular therapies.
PROCEPT BioRobotics (Nasdaq: PRCT) reported strong Q2 2024 financial results, with total revenue of $53.4 million, up 61% year-over-year. U.S. handpiece and consumables revenue surged 101% to $27.3 million. The company sold 47 robotic systems in the U.S. and increased its install base to 400 systems. International revenue grew 79% to $5.7 million.
Gross margin improved to 59%, up from 56% in the prior year. Despite higher operating expenses of $58.3 million, the company reduced its Adjusted EBITDA loss to $18.0 million. PROCEPT BioRobotics raised its full-year 2024 guidance, projecting revenue of $217.0 million (59% growth) and an improved Adjusted EBITDA loss of $67.5 million.
PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its plans to release second quarter 2024 financial results on August 1, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results.
Interested parties can access the call via a webcast link or dial-in registration for sell-side analysts. The live audio webcast and an archived recording will be available on the company's investor relations website. The webcast replay will be accessible for at least 90 days after the event.
PROCEPT BioRobotics announced the American Medical Association (AMA) has granted a new CPT Category I code for its Aquablation therapy, used to treat benign prostatic hyperplasia (BPH). This decision, driven by increased usage and clinical success, will take effect on January 1, 2026, replacing the current Category III CPT code. Until then, the existing code, 0421T, remains in use. This advancement underscores Aquablation therapy's safety, efficacy, and acceptance in treating BPH.
FAQ
What is the current stock price of Procept Biorobotics (PRCT)?
What is the market cap of Procept Biorobotics (PRCT)?
